Scancell Holdings (SCLP)

 

SCLP Share PerformanceMore

52 week high25.900 15/10/15
52 week low12.000 02/12/15
52 week change -10.450 (-41.80%)
4 week volume2,041,345 01/09/16

Media for (SCLP)

Presenter: Dr Richard Goodfellow
31/07/2015
Presenter: Dr Richard Goodfellow
02/06/2015

Latest NewsMore

Hardman Report: New frontiers in T-cell activation

RNS Number: 7395K Scancell Holdings Plc 26 September 2016 Hardman Research: New frontiers in T-cell activation New frontiers in T-cell activation and targeting: Scancell is a clinical stage pharmaceutical company developing two distinct flexible cancer immunotherapy platforms, each with broad applications. ImmunoBody is a DNA vaccine which stimulates hig...

Notice of AGM - Amendment

RNS Number: 7447K Scancell Holdings Plc 23 September 2016 23 September 2016 Scancell Holdings Plc Notice of AGM Amendment Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 18 October 2016. AGM details are as follows: Date: Tuesday 18 Octo...

Scancell Holdings schedules AGM

Scancell Holdings will hold its annual general meeting at The Kassam Stadium Grenoble Road, Oxford OX4 4XP on 18 Oct...

Notice of AGM

RNS Number: 7287K Scancell Holdings Plc 23 September 2016 23 September 2016 Scancell Holdings Plc Notice of AGM Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 18 October 2016. AGM details are as follows: Date: Tuesday 18 October, 2016 Tim...

Scancell widens H1 pretax loss

Scancell has widened its H1 pretax loss to 3.0m, from a year-ago loss of 2.8m. CEO John Chiplin commented: "We have cont...

Final Results

RNS Number: 0051K Scancell Holdings Plc 16 September 2016 16 September 2016 Scancell Holdings Plc ("Scancell" or the "Company") Final Results for the year ended 30 April 2016 Landmark four year survival achieved in resected SCIB1 patients Emerging pipeline of three products across five cancer indications Scancell Holdings plc, ('Scancell' or the 'Company') the d...

NewsMakers in the Biotech Industry Conference

RNS Number: 1299J Scancell Holdings Plc 07 September 2016 7 September 2016 Scancell Holdings Plc ("Scancell" or the "Company") Scancell to present at the 23rd Annual NewsMakers in the Biotech Industry Conference in NYC Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, announces that it w...

Appointment of Non-Executive Director

RNS Number: 7303H Scancell Holdings Plc 22 August 2016 22 August 2016 Scancell Holdings Plc ('Scancell' or the "Company") Dr Alan J. Lewis appointed as Non-Executive Director Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces the appointment of Dr Alan J. Lewis to the Board of Scancell as ...

Fundamental DataMore

EPS-1.14
Dividend yield0 %

Latest discussion posts More

  • Similar Products

    This appears to be a similar product , referred to as the wonder drug and possibly available on nhs soon, already available in ...
    17-Sep-2016
    charioteer
  • BUy, BUY, BUY

    An 836 share buy already - does this tell *US* something about September trends ??? Or, is it GFaw topping-up ???
    1-Sep-2016
    kipngail
  • The Grovelling Rat

    Sinks to a new low on LSE. Makes up a story and now apologises to avoid being banned. A RAT indeed.
    29-Aug-2016
    Aimbig

Users' HoldingsMore

Users who hold Scancell Holdings also hold..
LLOYDS GRP.19%
SIRIUS MINERALS12%
BARCLAYS11%
PREMAITHA11%
ROYAL BANK SCOT10%

Codes & Symbols

ISINGB00B63D3314
SymbolsSCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP